Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The management of poor ovarian responders (POR) remains the most challenging in In-Vitro
Fertilization (IVF). The incidence of POR ranges between 9 and 24% (Caprio F, et al, 2015).
POR refers to a reduction in the quantity of primordial follicle pool in reproductive age
group (Jirge, P. R., 2016, Sunkara, S. K., et al, 2014), in addition to a higher risk of
implantation failure (Kailasam C, et al, 2004).
To overcome this condition, fertility treatments using controlled ovarian stimulation along
with IVF is needed to achieve pregnancy. Despite the use of various treatments including high
dose gonadotropins, patients with POR have lower rates of pregnancy compared to patients with
normal ovarian response (Oudendijk, J. F., et al, 2011). Studies now suggest a variety of
regimens like the use of growth hormones, DHEA or androgens to improve the outcomes (Kyrou D,
et al, 2009). The main interest of this study is the use of myo-inositol prior to IVF cycles
for improvement of reproductive outcomes in poor ovarian responders.